Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1367
Peer-review started: July 31, 2020
First decision: September 21, 2020
Revised: September 29, 2020
Accepted: October 19, 2020
Article in press: October 19, 2020
Published online: December 27, 2020
Processing time: 139 Days and 14.3 Hours
The majority of hepatocellular carcinoma (HCC) cases are associated with the hepatitis B virus (HBV) infection. Autophagy related protein 9A (ATG9A) is a transmembrane protein required for autophagosome formation. In order to investigate the role of ATG9A in HBV-associated HCC, ATG9A protein expression was determined in tumor liver tissues and compared with adjacent nontumor tissues from HCC patients with or without HBV infection. In HBV-associated HCC tissues, ATG9A protein level was increased in tumor liver tissues, but not in cases of non-HBV HCC. Our findings suggested that ATG9A might be involved in HBV and cancer cell survival. Therefore, we aimed to analyze the function of ATG9A in HBV replication using RNA interference to evaluate the HBV DNA level using real-time PCR. In the present study, there were no significant differences between shATG9A-transfected HepG2.2.15 cells and the mock control. However, we found that silencing ATG9A affected apoptosis in HepG2.2.15 and HepG2 cell lines. Our results indicated that ATG9A might be partly involved in the survival of HCC. Thus, the inhibition of ATG9A together with other targets might be a potential drug target for HCC treatment.
Core Tip: Autophagy related protein 9A (ATG9A) protein expression was increased in tumor liver tissues compared to adjacent nontumor tissues from hepatocellular carcinoma (HCC) patients with hepatitis B virus infection. We showed that silencing ATG9A increased cell apoptosis of HepG2.2.15 and HepG2 cells. These results suggested that ATG9A protein is involved in the survival of HCC. The inhibition of ATG9A combined with other targets might be a potential drug target for HCC treatment.